286 related articles for article (PubMed ID: 10422348)
1. [Chiral compounds and their pharmacologic effects].
Slováková A; Hutt AJ
Ceska Slov Farm; 1999 May; 48(3):107-12. PubMed ID: 10422348
[TBL] [Abstract][Full Text] [Related]
2. Three-dimensional view of pharmacology.
Wainer IW
Am J Hosp Pharm; 1992 Sep; 49(9 Suppl 1):S4-8. PubMed ID: 1530004
[TBL] [Abstract][Full Text] [Related]
3. Application of thin-layer chromatography in enantiomeric chiral analysis-an overview.
Aboul-Enein HY; El-Awady MI; Heard CM; Nicholls PJ
Biomed Chromatogr; 1999 Dec; 13(8):531-7. PubMed ID: 10611607
[TBL] [Abstract][Full Text] [Related]
4. Differential properties of enantiomers of commercially available racemates.
Gulati V
J Indian Med Assoc; 2007 Apr; 105(4):173-4, 176. PubMed ID: 17822184
[TBL] [Abstract][Full Text] [Related]
5. Biological significance of the enantiomeric purity of drugs.
Waldeck B
Chirality; 1993; 5(5):350-5. PubMed ID: 8398592
[TBL] [Abstract][Full Text] [Related]
6. A consideration of the patentability of enantiomers in the pharmaceutical industry in the United States.
Miller CP; Ullrich JW
Chirality; 2008 Jun; 20(6):762-70. PubMed ID: 18200591
[TBL] [Abstract][Full Text] [Related]
7. Stereoselectivity in drug metabolism.
Lu H
Expert Opin Drug Metab Toxicol; 2007 Apr; 3(2):149-58. PubMed ID: 17428147
[TBL] [Abstract][Full Text] [Related]
8. [Chiral switch: pure enantiomers of drugs instead of racemic mixtures].
Valentová J; Hutt AJ
Ceska Slov Farm; 2004 Nov; 53(6):285-93. PubMed ID: 15630994
[TBL] [Abstract][Full Text] [Related]
9. [Chirality and drugs].
Testa B; Reist M; Carrupt PA
Ann Pharm Fr; 2000 Jul; 58(4):239-46. PubMed ID: 10915971
[TBL] [Abstract][Full Text] [Related]
10. Pharmacologically active compounds in the environment and their chirality.
Kasprzyk-Hordern B
Chem Soc Rev; 2010 Nov; 39(11):4466-503. PubMed ID: 20852776
[TBL] [Abstract][Full Text] [Related]
11. [Preparations and biological properties of chiral compounds].
Sinko G
Arh Hig Rada Toksikol; 2005 Dec; 56(4):351-61. PubMed ID: 16370519
[TBL] [Abstract][Full Text] [Related]
12. Chirality and its implications in transdermal drug development.
Reddy IK; Kommuru TR; Zaghloul AA; Khan MA
Crit Rev Ther Drug Carrier Syst; 2000; 17(4):285-325. PubMed ID: 10958245
[TBL] [Abstract][Full Text] [Related]
13. Computational validation of the importance of absolute stereochemistry in virtual screening.
Brooks WH; Daniel KG; Sung SS; Guida WC
J Chem Inf Model; 2008 Mar; 48(3):639-45. PubMed ID: 18266348
[TBL] [Abstract][Full Text] [Related]
14. Drug Stereochemistry: A Prodigy For Pharmacology and Drug Development.
Gandhi K; Shah U; Patel S
Curr Drug Discov Technol; 2020; 17(5):565-573. PubMed ID: 31057115
[TBL] [Abstract][Full Text] [Related]
15. Chirality in ocular agents.
Leonov A; Bielory L
Curr Opin Allergy Clin Immunol; 2007 Oct; 7(5):418-23. PubMed ID: 17873582
[TBL] [Abstract][Full Text] [Related]
16. The development of chiral drugs.
Campbell DB
Acta Pharm Nord; 1990; 2(3):217-26. PubMed ID: 2200432
[TBL] [Abstract][Full Text] [Related]
17. The strategy of enantiomer patents of drugs.
Agranat I; Wainschtein SR
Drug Discov Today; 2010 Mar; 15(5-6):163-70. PubMed ID: 20116449
[TBL] [Abstract][Full Text] [Related]
18. [Stereochemistry--an overlooked problem in medical treatment and research].
Mikkelsen EO
Ugeskr Laeger; 1990 Jul; 152(28):2029-32. PubMed ID: 2195737
[TBL] [Abstract][Full Text] [Related]
19. Drug disposition in three dimensions: an update on stereoselectivity in pharmacokinetics.
Brocks DR
Biopharm Drug Dispos; 2006 Nov; 27(8):387-406. PubMed ID: 16944450
[TBL] [Abstract][Full Text] [Related]
20. Chirality and pharmacokinetics: an area of neglected dimensionality?
Hutt AJ
Drug Metabol Drug Interact; 2007; 22(2-3):79-112. PubMed ID: 17708062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
